Cytosorbents Cor (CTSO) Stock Price, Quote & News

Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. The company's flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflammation, organ failure, cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediator...

Industry: Medical Devices

Sector: Healthcare

Phone: 732 329 8885

Fax: 732 329 8650

Website: www.cytosorbents.com

Address:

305 College Road East, Princeton, United States

DARKP00L Dec. 16 at 6:22 PM

$CTSO 13:03 on Dec. 16 2025 D. Boral Capital Maintains Buy on CytoSorbents, Maintains $10 Price Target #tradeideas

1 · Reply

JarvisFlow Dec. 16 at 6:03 PM

D. Boral Capital has updated their rating for CytoSorbents ( $CTSO ) to Buy with a price target of 10.

1 · Reply

melodicalmind Dec. 16 at 3:04 AM

$CTSO might be, relatively, one of the safest micro-cap convictions right now. Real people with proven background, trying to solve real problems. Impressed.

1 · Reply

NJ125 Dec. 10 at 10:50 PM

$CTSO toilet bound European German order ? What is happening to U.S. employee count?

1 · Reply

JohnTrack Dec. 10 at 3:04 PM

$CTSO watching for squeeze vibes...

1 · Reply

JohnTrack Dec. 10 at 12:17 PM

$CTSO brief note hit the wire https://www.rapidticker.com/news/ctso-cytosorbents-to-participate-in-a-71a67b

0 · Reply

Kenzo71 Dec. 2 at 2:22 PM

$CTSO has now closed below one dollar per share every day since August 20, 2025. That equates to 104 days. The Delisting watch has begun. !

1 · Reply

Steelometer Nov. 24 at 7:46 PM

$CTSO What is going on the Last 3 Trading Days?

2 · Reply

ZacksSCR Nov. 17 at 2:26 PM

$CTSO: CytoSorbents High Margin Revenue Growth Supports Price Target of $4.00 https://buff.ly/20ySDCO

0 · Reply

JarvisFlow Nov. 14 at 8:45 PM

D. Boral Capital has adjusted their stance on CytoSorbents ( $CTSO ), setting the rating to Buy with a target price of 10.

1 · Reply

Cytosorbents Corporation (CTSO) Discusses Progress in Blood-Purification Programs and DrugSorb-ATR's Regulatory Path Transcript

Dec 10, 2025, 7:00 AM EST - 18 days ago

CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025

Nov 17, 2025, 5:42 PM EST - 5 weeks ago

Updated: CytoSorbents to Present at the Jefferies Global Healthcare Conference in London

Nov 13, 2025, 7:21 PM EST - 6 weeks ago

Cytosorbents Corporation (CTSO) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 4:05 PM EST - 6 weeks ago

CytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 11, 2025, 7:00 AM EST - 6 weeks ago

CytoSorbents to Participate at the Jefferies Global Healthcare Conference in London

Oct 30, 2025, 7:00 AM EDT - 2 months ago

CytoSorbents to Report Third Quarter 2025 Financial Results and Recent Business Highlights

Oct 28, 2025, 7:00 AM EDT - 2 months ago

In Memoriam: Dr. Robert Hawes Bartlett (1939-2025) - Father of Extracorporeal Membrane Oxygenation (ECMO) and Former CytoSorbents Chief Medical Officer

Sep 29, 2025, 7:00 AM EDT - 3 months ago

CytoSorbents to Showcase Pioneering New Cardiac Surgery Data in Key Applications at the EACTS 2025 Annual Meeting in Copenhagen

Sep 16, 2025, 7:00 AM EDT - 3 months ago

CytoSorbents Provides DrugSorb-ATR Regulatory Update

Sep 8, 2025, 7:00 AM EDT - 3 months ago

CytoSorbents To Host Global Webinar on "Turning the Tide in Sepsis and Septic Shock: Real World Insights with CytoSorb" in Recognition of World Sepsis Day

Sep 5, 2025, 7:00 AM EDT - 4 months ago

CytoSorbents to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 20, 2025, 7:00 AM EDT - 4 months ago

CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR

Aug 8, 2025, 1:22 PM EDT - 5 months ago

Cytosorbents Corporation (CTSO) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:00 PM EDT - 5 months ago

CytoSorbents Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 7:00 AM EDT - 5 months ago

CytoSorbents Leads a New Era in Sepsis Treatment

Jul 29, 2025, 7:00 AM EDT - 5 months ago

CytoSorbents to Report Second Quarter 2025 Financial Results and Recent Business Highlights

Jul 2, 2025, 7:00 AM EDT - 6 months ago

CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR

Jun 24, 2025, 7:00 AM EDT - 6 months ago

CytoSorbents Files Appeal with U.S. FDA for Supervisory Review of its De Novo Request for DrugSorb™-ATR

May 29, 2025, 7:00 AM EDT - 7 months ago

CytoSorbents to Participate at the Jefferies Global Healthcare Conference

May 22, 2025, 9:27 AM EDT - 7 months ago

CytoSorbents Therapy Significantly Reduces Bleeding in Urgent CABG Patients on Ticagrelor in New Data Presented at EuroPCR 2025

May 14, 2025, 9:37 PM EDT - 8 months ago

Cytosorbents Corporation (CTSO) Q1 2025 Earnings Call Transcript

May 14, 2025, 4:01 PM EDT - 8 months ago

CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 4:15 PM EDT - 8 months ago

CytoSorbents Provides Regulatory Update for DrugSorb-ATR

Apr 29, 2025, 7:00 AM EDT - 8 months ago

CytoSorbents to Report First Quarter 2025 Financial Results and Recent Business Highlights

Apr 21, 2025, 7:00 AM EDT - 8 months ago

CytoSorbents Receives Approximately $1.7 Million from the New Jersey Business Tax Certificate Transfer Program

Apr 17, 2025, 7:00 AM EDT - 9 months ago

CytoSorbents Appoints Melanie Grossman, CPA as Vice President and Corporate Controller

Apr 14, 2025, 7:00 AM EDT - 9 months ago

CytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America

Apr 4, 2025, 7:00 AM EDT - 9 months ago

CytoSorbents Extends Expiration Date of Outstanding Series B Right Warrants

Mar 31, 2025, 7:51 PM EDT - 9 months ago

Cytosorbents Corporation (CTSO) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 4:15 PM EDT - 9 months ago

CytoSorbents Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Mar 21, 2025, 7:00 AM EDT - 10 months ago

CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit

Mar 4, 2025, 7:00 AM EST - 10 months ago

CytoSorbents Postpones Earnings Release to Allow More Time to Complete Annual Audit Following the Passing of Corporate Controller

Jan 3, 2025, 7:00 AM EST - 1 year ago

CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue

Dec 12, 2024, 7:00 AM EST - 1 year ago

CytoSorbents to Host Investor Meetings in San Francisco During J.P. Morgan Healthcare Conference Week

Nov 11, 2024, 7:30 AM EST - 1 year ago

CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India

Nov 9, 2024, 1:20 PM EST - 1 year ago

Cytosorbents Corporation (CTSO) Q3 2024 Earnings Call Transcript

Oct 1, 2024, 7:00 AM EDT - 1 year ago

CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update

Aug 27, 2024, 7:00 AM EDT - 1 year ago

CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference

Aug 16, 2024, 4:05 PM EDT - 1 year ago

CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 13, 2024, 10:31 PM EDT - 1 year ago

Cytosorbents Corporation (CTSO) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 4:19 PM EDT - 1 year ago

CytoSorbents Reports Second Quarter 2024 Financial and Operational Results

Aug 13, 2024, 4:18 PM EDT - 1 year ago

CytoSorbents Appoints Peter J. Mariani Chief Financial Officer

Aug 7, 2024, 7:00 AM EDT - 1 year ago

CytoSorbents to Report Second Quarter 2024 Operating and Financial Results

Aug 1, 2024, 7:00 AM EDT - 1 year ago

CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement

Jul 30, 2024, 2:00 AM EDT - 1 year ago

CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website

Jul 17, 2024, 7:00 AM EDT - 1 year ago

CytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress

Jul 2, 2024, 7:00 AM EDT - 1 year ago

CytoSorbents Secures $20 Million Credit Facility

Jun 5, 2024, 7:00 AM EDT - 1 year ago

CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting

May 9, 2024, 11:01 PM EDT - 1 year ago

Cytosorbents Corporation (CTSO) Q1 2024 Earnings Call Transcript

DARKP00L Dec. 16 at 6:22 PM

$CTSO 13:03 on Dec. 16 2025 D. Boral Capital Maintains Buy on CytoSorbents, Maintains $10 Price Target #tradeideas

1 · Reply

JarvisFlow Dec. 16 at 6:03 PM

D. Boral Capital has updated their rating for CytoSorbents ( $CTSO ) to Buy with a price target of 10.

1 · Reply

melodicalmind Dec. 16 at 3:04 AM

$CTSO might be, relatively, one of the safest micro-cap convictions right now. Real people with proven background, trying to solve real problems. Impressed.

1 · Reply

NJ125 Dec. 10 at 10:50 PM

$CTSO toilet bound European German order ? What is happening to U.S. employee count?

1 · Reply

JohnTrack Dec. 10 at 3:04 PM

$CTSO watching for squeeze vibes...

1 · Reply

JohnTrack Dec. 10 at 12:17 PM

$CTSO brief note hit the wire https://www.rapidticker.com/news/ctso-cytosorbents-to-participate-in-a-71a67b

0 · Reply

Kenzo71 Dec. 2 at 2:22 PM

$CTSO has now closed below one dollar per share every day since August 20, 2025. That equates to 104 days. The Delisting watch has begun. !

1 · Reply

Steelometer Nov. 24 at 7:46 PM

$CTSO What is going on the Last 3 Trading Days?

2 · Reply

ZacksSCR Nov. 17 at 2:26 PM

$CTSO: CytoSorbents High Margin Revenue Growth Supports Price Target of $4.00 https://buff.ly/20ySDCO

0 · Reply

JarvisFlow Nov. 14 at 8:45 PM

D. Boral Capital has adjusted their stance on CytoSorbents ( $CTSO ), setting the rating to Buy with a target price of 10.

1 · Reply

JarvisFlow Nov. 14 at 1:08 PM

HC Wainwright & Co. updates rating for CytoSorbents ( $CTSO ) to Neutral, target set at 1 → 0.75.

0 · Reply

Kenzo71 Nov. 14 at 2:49 AM

$CTSO Never a good and compelling story when cash flow break even is achieved from cost-cutting. Sales growth and revenue growth are always the much preferred approach. Unfortunately the call offered very little opportunity for future growth prior to a future FDA decision re: DrugSorb ATR and the earliest such a decision might be forthcoming is mid 2026. I would stay away from CTSO and avoid any investment here until the FDA makes a decision on DrugSorb-ATR and we have more clarity on the Company’s roll-out strategy assuming their product is approved.

0 · Reply

NJ125 Nov. 13 at 10:25 PM

$CTSO as some expected layoffs continue. Risk increased with short window for fda resubmission and cash burn rate. Is Risk of preemptive bankruptcy filing in first half 2026 imcreasing? Confidence in senior management? Too late for Board to make changes? Expect year-end tax selling could take stock lower?!

0 · Reply

d_risk Nov. 13 at 9:44 PM

$CTSO - Cytosorbents Corporation Common Stock - 10Q - Updated Risk Factors CTSO faces ongoing regulatory hurdles after FDA and Health Canada setbacks, heightened uncertainty around market acceptance and reimbursement for its products, and new risk of Nasdaq delisting impacting stock liquidity. #Biotechnology #StockLiquidity #ReimbursementUncertainty #MarketAcceptance #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/CTSO/10-Q/2025-11-13

0 · Reply